Dr. Samie Jaffrey's team will study metabolite-RNA interactions to comprehensively map and characterize their role in regulating messenger RNA levels. Their findings could lead to new therapeutic opportunities for diseases such as cancer, neurodegeneration, and metabolic disorders.
Dr. Elemento's team will develop an AI-human discovery engine to generate hypotheses from human cell and tissue data, test them using robotics testing platforms, and refine the process with human oversight. The goal is to discover new mechanisms that can be targeted pharmacologically and democratize access to AI tools for research.
Researchers have discovered a new cell type that helps stabilize the vascular network supplying oxygen to growing cardiac muscle. This discovery provides novel insights into human heart development and may guide future efforts to promote heart regeneration after injury.
New research suggests that neck lymph node removal may interfere with cerebrospinal fluid drainage, contributing to cognitive impairment. Patients undergoing cervical lymphadenectomy had a higher rate of cognitive impairment than the general population.
Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...
Researchers have identified the mechanism by which a molecule within cells tunes the sensitivity of the eyes to light, offering a potential treatment for eye diseases. The study found that a phospholipid called PIP2 inhibits the activation of ion channels in retinal cells, regulating light sensitivity.
Researchers found that exercise can modulate changes in the bladder caused by chronic stress, reducing pain and urinary frequency in IC/BPS. Voluntary exercise may offer a non-surgical, non-pharmacologic way to treat stress-linked urinary tract conditions.
Researchers at Weill Cornell Medicine will explore new approaches to shorten TB treatment, using gene silencing and genetic interactions to target bacterial survival mechanisms. The goal is to develop shorter, safer, and simpler cures for TB, reducing treatment duration and overcoming drug resistance.
Interferon-alpha treatment depletes mutant blood stem cells and induces production of infection-fighting white blood cells, potentially benefiting patients with myeloproliferative neoplasms. The study's findings provide new strategies for managing these blood cancers.
Researchers have discovered a surprising diversity of metabotropic glutamate receptor-beta arrestin interactions, which could help explain why previous drugs targeting these receptors have failed. The studies, led by Weill Cornell Medicine investigators, provide a foundational model for future mechanistic and drug-development work.
Weill Cornell Medicine and Rutgers Health have received a four-year, $3 million grant to build a research center focused on HIV-associated brain injury. The center will help investigators access shared molecular and computational tools to define the mechanisms of brain injury and identify new therapeutic opportunities.
A new preclinical study found that glucocorticoid-rhythm disruption concentrates insulin resistance in skeletal muscle while preserving key insulin responses in fat tissue and liver, leading to a different type of obesity. This allows fat tissue to continue storing lipids, while the liver remains largely protected from fat accumulation.
Researchers have discovered a stem cell that contributes to lumbar spinal stenosis, a condition characterized by enlarged ligaments and nerve compression. The stem cell's hyperactivity may lead to the development of new treatment options, including drugs used to manage high blood pressure.
Dr. Zachary Grinspan has been awarded a $1.6 million CDC grant to research childhood epilepsy. The CEPIE study will combine data from various sources to determine the incidence of epilepsy in US children, identify types of epilepsy, and predict risk factors.
A preliminary study by Weill Cornell Medicine investigators found that antifungal therapy can reduce IBD symptoms and improve the gut microbiome in patients with Candida overgrowth. The study compared the effects of two weeks of treatment with nystatin or fluconazole in 53 patients with mild-to-moderate Crohn's disease or ulcerative co...
A team of Weill Cornell Medicine investigators developed a computer model that helps scientists efficiently develop protein-degrading therapies. The new model could lead to more targeted treatments for cancer, particularly those with cancer-causing mutations.
Tuberculosis bacteria can evolve to withstand airborne transmission and generate antibiotic resistance, according to a new study. Researchers identified a DNA repair gene called Mfd that helps certain drug-resistant strains survive transmission.
Weill Cornell Medicine has created a new research department, the Department of Systems and Computational Biomedicine, with Dr. Dan Landau as its inaugural chair. The department will harness cutting-edge computational approaches to illuminate how disease develops and forge innovative prevention and treatment strategies.
Prostate cancer cells rewire amino acid metabolism to override normal brakes on cholesterol production, fueling hormone therapy resistance. Restricting isoleucine and valine in the diet may slow tumor growth and improve treatment response, while boosting propionyl-CoA levels promotes tumor growth.
Studies in Pakistan's trauma registry found that traumatic brain injuries are associated with high death and disability rates long after the initial injury, even in moderate cases. Patients remain vulnerable during hospital discharge transition.
Researchers at Weill Cornell Medicine have identified structural changes that enable the LRRK2 protein to become overactive, a key step in Parkinson's disease progression. Understanding these changes is crucial for developing targeted therapies to slow or halt the disease.
A new study suggests that artificial intelligence can enhance the implementation of Medicaid work requirements by helping state agencies keep eligible individuals enrolled. AI tools can analyze existing databases to verify compliance or exemption status, reducing documentation difficulties and administrative complexities. However, huma...
A phase 3 clinical trial led by Weill Cornell Medicine shows that adding a targeted radionuclide therapy drug to backbone therapy reduces disease progression in patients with PSMA-positive metastatic prostate cancer. The treatment may delay symptom progression and improve patient outcomes.
A study led by Dr. Michael Harrison found that regional dips in oxygen levels serve as a signal for the coordinated growth of heart muscle and coronary vessels. The system operates as a self-limiting feedback loop, with epicardial cells detecting hypoxia to activate genes that orchestrate expansion.
Researchers have identified a protein called integrin alpha-5 as the cargo in tumor-derived extracellular vesicles that promotes lung blood vessel leakiness and lung metastasis in several types of cancer. The discovery could lead to new ways of monitoring and reducing lung metastasis risk in cancer patients.
Researchers at Weill Cornell Medicine discovered that a protein called BRG1 helps protect cells from ferroptosis, an iron-dependent form of cell death triggered by BTK inhibitors. This finding reveals a potential new therapeutic vulnerability to overcome drug resistance and extend treatment benefits for patients with B-cell cancers.
Research suggests that an overactive immune response in the brain may play a role in Dravet Syndrome, leading to frequent seizures and developmental challenges. Blocking an inflammatory pathway called cGAS-STING-interferon signaling could lead to new therapeutic strategies for epilepsy disorders.
Researchers developed a library of 220 patient-derived tumor organoids, showing promise in screening treatments and recapitulating the tumor immune microenvironment. These models may enable personalized cancer treatment selection, using organoids as avatars during clinical trials.
Researchers developed a new method to assess patients with myelodysplastic neoplasms (MDS), a form of blood cancer. The MDS-Microarchitectural Perturbation Score (MDS-MAPS) tool uses AI to analyze bone marrow samples, providing a score that reflects disease severity.
The grant supports the development of therapies with fewer side effects for triple-negative breast cancer, a highly aggressive and difficult-to-treat form of breast cancer. The researchers aim to target UBR5 protein, which is overproduced in aggressive breast cancers and several other malignancies.
A new compound called ampyrone safely increases melanin production in human skin, offering a potential treatment for hypopigmentation disorders. The discovery could improve visual function and enhance patient quality of life for those with severe genetic forms of albinism.
BioVenture eLab will recruit international founders and provide resources for Weill Cornell faculty and trainees, aiming to generate entrepreneurship opportunities from within the academic medical institution's community. The program will also enable the selection of global entrepreneurs based on scientific data and business strategy.
Researchers uncover the role of DNA hypomethylation in driving glioma progression from slow-growing to aggressive tumors. The study's findings offer new insights into the biology of IDH gliomas, which can inform future treatments and prognostic measures for patients.
Study identifies binding pocket on sodium ion channels where anesthetics like sevoflurane stabilize in inactive state, reducing neuronal activity. The findings may enable the design of safer, more selective anesthetics with fewer side effects.
Researchers found that a small subset of T cells, called stem T cells, are responsible for making new T cells and replenishing them in chronic disease. Boosting these rare stem T cells overcame T cell exhaustion in chronic infection and removed overactive immune cells in type 1 diabetes.
Researchers found that GATA6 expression is reduced in liver metastases, correlating with poorer clinical outcomes. Losing GATA6 allows cancer cells to change their identity and become more adaptable, leading to metastasis.
Dr. Dan Landau receives Lotus Award for research on uncovering immunotherapy targets in ovarian cancer. He aims to develop new therapeutic perspectives using single-cell profiling techniques and identify unusual variants of proteins as potential targets.
A new fluorescence imaging-based technique allows researchers to measure individual scramblase protein activity rates, revealing new findings and broad applicability. This enables precise study of key scramblases and their potential role in various biological processes and diseases.
Researchers discovered that engineered nanoparticles directly induce tumor-cell death while transforming the immune microenvironment, supporting further investigation of their therapeutic potential. The particles push cancer cells toward ferroptosis and convert inert immune cells into robust antitumor activity.
Researchers developed a metal-free carbon monoxide prodrug that significantly reduced metastatic tumor growth in pancreatic and triple-negative breast cancer models without signs of toxicity. The prodrug, CO-116, works by disrupting a signaling pathway that promotes cancer cell migration and metastasis.
A study published in Lancet Planetary Health found that most national climate adaptation plans fail to fully integrate health needs or engage populations at risk from climate change. Key gaps include inadequate monitoring and evaluation, insufficient budgeting, and lack of engagement with vulnerable groups.
The American Heart Association warns that extreme heat events are increasing, posing significant cardiovascular risks. The statement outlines contributing factors and recommendations to mitigate these risks, particularly for vulnerable populations such as older adults and those with low incomes.
Dr. Elizabeth Kim, a researcher at Weill Cornell Medicine, has received the 2026 Tri-Institutional Breakout Award for her work on drug targeting of HCN1, an ion channel protein linked to diseases like epilepsy. Her study, published in Nature in 2024, discovered how propofol can restore mutant channels to normal function.
A breakthrough single-cell method, D&D-seq, enables researchers to map DNA-protein interactions, overcoming technical limitations of current methods. This technology is expected to revolutionize the study of gene regulation and its role in diseases.
A recent clinical trial demonstrated that an all-oral drug combination of decitabine-cedazuridine and venetoclax is effective in treating acute myeloid leukemia (AML) in older patients. The regimen showed strong response rates and survival outcomes, with nearly half of patients achieving complete response.
Researchers aim to build a cohort of 2,000 AYA cancer survivors in NYC to study the short- and long-term effects of newer cancer treatments. The study will focus on challenges such as fertility and sexual health concerns, as well as financial stress.
Researchers developed a new cardiac MRI-based measurement, eRVEF, to assess tricuspid regurgitation and improve mortality risk prediction. The study found that eRVEF predicted adverse outcomes better than traditional measures.
A new preclinical study suggests that targeting tumor-specific inflammatory processes could enhance the efficacy of some anticancer therapies and prevent drug resistance. The researchers found that tumors treated with KRAS inhibitors often developed inflammation-related gene expression changes, which contributed to drug resistance.
The updated guidelines recommend treating high cholesterol earlier and using advanced tests like Lp(a) and CAC scans to identify hidden risks. Primary care clinicians play a crucial role in implementing these changes, but challenges exist due to short office visits and insurance coverage limitations.
Pregnancy-related cardiovascular complications account for 20-30% of maternal deaths in the US. Researchers analyzed claims data to find that underlying cardiovascular risk drives these events, rather than older age. This may encourage doctors to address cardiovascular health before pregnancy.